Pfizer Inc. Files 8-K Report
Ticker: PFE · Form: 8-K · Filed: 2025-05-19T00:00:00.000Z
Sentiment: neutral
Topics: regulatory-filing, 8-K
Related Tickers: PFE
TL;DR
Pfizer filed a standard 8-K, no major news.
AI Summary
On May 14, 2025, Pfizer Inc. filed an 8-K report detailing other events and financial statements. The filing does not disclose specific new material events or financial figures but serves as a standard regulatory update.
Why It Matters
This filing is a routine regulatory update from Pfizer Inc., indicating no immediate material changes or significant new disclosures for investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K with no new material events or financial disclosures, indicating low immediate risk.
Key Players & Entities
- Pfizer Inc. (company) — Registrant
- May 14, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 1-3619 (other) — Commission File Number
- 13-5315170 (other) — I.R.S. Employer Identification No.
- 66 Hudson Boulevard East, New York, New York 10001-2192 (address) — Principal executive offices
- (212) 733-2323 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Pfizer Inc.?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of May 14, 2025.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is May 14, 2025.
In which state is Pfizer Inc. incorporated?
Pfizer Inc. is incorporated in Delaware.
What is Pfizer Inc.'s principal executive office address?
Pfizer Inc.'s principal executive office is located at 66 Hudson Boulevard East, New York, New York 10001-2192.
Does this filing disclose any specific new material events or financial results?
Based on the provided text, this filing appears to be a standard 8-K report and does not explicitly disclose specific new material events or financial results beyond the general categories of 'Other Events' and 'Financial Statements and Exhibits'.
From the Filing
0001193125-25-122480.txt : 20250519 0001193125-25-122480.hdr.sgml : 20250519 20250519162915 ACCESSION NUMBER: 0001193125-25-122480 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 21 CONFORMED PERIOD OF REPORT: 20250514 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250519 DATE AS OF CHANGE: 20250519 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 25964405 BUSINESS ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 8-K 1 d60311d8k.htm 8-K 8-K PFIZER INC false 0000078003 0000078003 2025-05-14 2025-05-14 0000078003 us-gaap:CommonStockMember 2025-05-14 2025-05-14 0000078003 us-gaap:DeferrableNotesMember 2025-05-14 2025-05-14     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 14, 2025     PFIZER INC. (Exact name of registrant as specified in its charter)       Delaware   1-3619   13-5315170 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   66 Hudson Boulevard East   New York , New York   10001-2192 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: (212) 733-2323   (Former name or former address, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.05 par value   PFE   New York Stock Exchange 1.000% Notes due 2027   PFE27   New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company   ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐       Item 8.01 Other Events. On May 19, 2025, Pfizer Netherlands International Finance B.V. (the “Issuer”), a private limited liability company ( besloten vennootschap met beperkte aansprakelijkheid ) under Dutch law and a wholly-owned subsidiary of Pfizer Inc. (the “Company”), completed a public offering of €750,000,000 aggregate principal amount of 2.875% Notes due 2